Blog
RSS FeedPosted by Michael Wonder on 13 Oct 2020
Daewoong's antipyretic unable to get insurance benefits
13 October 2020 - Daewoong Pharmaceutical has failed to list Fiblast (trafermin), a burn treatment drug developed by Japan's Kaken ...
Posted by Michael Wonder on 14 Sep 2020
Will Tagrisso win insurance benefits in Korea, too?
14 September 2020 - AstraZeneca’s Tagrisso, targeted therapy for lung cancer, has won recognition as the first-line standard treatment for ...
Posted by Michael Wonder on 31 Aug 2020
‘Korea should introduce indication-specific drug pricing’
31 August 2020 - “Korea must introduce a system to apply different prices for a drug’s multiple indications, to guarantee ...
Posted by Michael Wonder on 27 Aug 2020
Drug makers to sue government for limiting choline alfoscerate benefit
27 August 2020 - Manufacturers of choline alfoscerate, a dementia drug, are reportedly preparing to file an administrative lawsuit against ...
Posted by Michael Wonder on 12 Aug 2020
Takeda expects more effective IBD treatment with Kynteles' expanded reimbursement
12 August 2020 - Takeda Korea is strengthening its position in the domestic inflammatory bowel disease market with Kynteles receiving ...
Posted by Michael Wonder on 11 Aug 2020
Petitioner demands insurance benefit for breast cancer drug Kadcyla
11 August 2020 - A woman has requested that the government grant reimbursement for using Kadcyla of Roche in treating ...
Posted by Michael Wonder on 07 Aug 2020
Rheumatoid arthritis drug Rinvoq gets insurance benefit
7 August 2020 - AbbVie Korea’s rheumatoid arthritis treatment Rinvoq (upadacitinib) has obtained the national health insurance benefit. ...
Posted by Michael Wonder on 03 Aug 2020
ISPOR announces Virtual ISPOR Asia Pacific 2020
3 August 2020 - ISPOR—The Professional Society for Health Economics and Outcomes Research announced its Virtual ISPOR Asia Pacific 2020 ...
Posted by Michael Wonder on 27 Jul 2020
Pilot run of herbal medicine reimbursement starts in October
27 July 2020 - The Government said it would run a pilot program to allow herbal medicines to receive the ...
Posted by Michael Wonder on 23 Jul 2020
'Severe atopic dermatitis drug too expensive for adolescents'
21 July 2020 - The drug regulator expanded approval for Dupixent (dupilumab), a treatment for severe atopic dermatitis, from adults ...
Posted by Michael Wonder on 09 Jul 2020
Drugmakers appeal limited insurance benefit for dementia drug choline alfoscerate
9 July 2020 - Sixty-six manufacturers of choline alfoscerate, a dementia drug, filed an appeal to the Health Insurance Review ...
Posted by Michael Wonder on 09 Jul 2020
'Xolair’s reimbursement will change treatment paradigm for asthma patients'
9 July 2020 - Novartis Korea will be able to strengthen its position in the severe allergic asthma market with ...
Posted by Michael Wonder on 30 Jun 2020
EMA and Korean Ministry of Food and Drug Safety to share confidential COVID-19 information
30 June 2020 - EMA and the Ministry of Food and Drug Safety of the Republic of Korea have signed ...
Posted by Michael Wonder on 29 Jun 2020
‘Government should lower prices of generic drugs’
29 June 2020 - “Our policy should aim at reaching the OECD average of general drug use, additionally cut generic ...
Posted by Michael Wonder on 14 Jun 2020
Dementia drug choline alfoscerate to get limited insurance benefit
12 June 2020 - The government has allowed choline alfoscerate, a dementia drug, to continue to receive the national health ...